Literature DB >> 33206936

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.

Jenny Klintman1,2,3, Niamh Appleby1,2,4, Basile Stamatopoulos1,5, Katie Ridout1,2, Toby A Eyre4, Pauline Robbe1,2, Laura Lopez Pascua1,2, Samantha J L Knight6,7, Helene Dreau1,2, Maite Cabes4, Niko Popitsch6,7,8, Mats Ehinger9, Jose I Martín-Subero10,11, Elías Campo10, Robert Månsson12,13, Davide Rossi14, Jenny C Taylor6,7, Dimitrios V Vavoulis1,2,6,7, Anna Schuh1,2,4,6.   

Abstract

The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we conducted whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS) from 17 patients recruited into a clinical trial (CHOP-O). We found that tissue-RS was enriched for mutations in poor-risk CLL drivers and genes in the DNA damage response (DDR) pathway. In addition, we identified genomic aberrations not previously implicated in RS, including the protein tyrosine phosphatase receptor (PTPRD) and tumor necrosis factor receptor-associated factor 3 (TRAF3). In the noncoding genome, we discovered activation-induced cytidine deaminase-related and unrelated kataegis in tissue-RS affecting regulatory regions of key immune-regulatory genes. These include BTG2, CXCR4, NFATC1, PAX5, NOTCH-1, SLC44A5, FCRL3, SELL, TNIP2, and TRIM13. Furthermore, differences between the global mutation signatures of pairs of PB-CLL and tissue-RS samples implicate DDR as the dominant mechanism driving transformation. Pathway-based clonal deconvolution analysis showed that genes in the MAPK and DDR pathways demonstrate high clonal-expansion probability. Direct comparison of nodal-CLL and tissue-RS pairs from an independent cohort confirmed differential expression of the same pathways by RNA expression profiling. Our integrated analysis of WGS and RNA expression data significantly extends previous targeted approaches, which were limited by the lack of germline samples, and it facilitates the identification of novel genomic correlates implicated in RS transformation, which could be targeted therapeutically. Our results inform the future selection of investigative agents for a UK clinical platform study. This trial was registered at www.clinicaltrials.gov as #NCT03899337.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33206936      PMCID: PMC8163497          DOI: 10.1182/blood.2020005650

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  73 in total

1.  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Robert J Manning; Christina Tripsas; Christopher J Patterson; Patricia Sheehy; Steven P Treon
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

2.  Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.

Authors:  Kilannin Krysiak; Felicia Gomez; Brian S White; Matthew Matlock; Christopher A Miller; Lee Trani; Catrina C Fronick; Robert S Fulton; Friederike Kreisel; Amanda F Cashen; Kenneth R Carson; Melissa M Berrien-Elliott; Nancy L Bartlett; Malachi Griffith; Obi L Griffith; Todd A Fehniger
Journal:  Blood       Date:  2016-11-14       Impact factor: 22.113

3.  TRIM13 inhibited cell proliferation and induced cell apoptosis by regulating NF-κB pathway in non-small-cell lung carcinoma cells.

Authors:  Ling Xu; Qi Wu; Xifa Zhou; Qiyong Wu; Mingming Fang
Journal:  Gene       Date:  2019-07-26       Impact factor: 3.688

Review 4.  Richter's transformation in chronic lymphocytic leukemia.

Authors:  Apostolia-Maria Tsimberidou; Michael J Keating
Journal:  Semin Oncol       Date:  2006-04       Impact factor: 4.929

5.  The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.

Authors:  Selvaraju Veeriah; Cameron Brennan; Shasha Meng; Bhuvanesh Singh; James A Fagin; David B Solit; Philip B Paty; Dan Rohle; Igor Vivanco; Juliann Chmielecki; William Pao; Marc Ladanyi; William L Gerald; Linda Liau; Timothy C Cloughesy; Paul S Mischel; Chris Sander; Barry Taylor; Nikolaus Schultz; John Major; Adriana Heguy; Fang Fang; Ingo K Mellinghoff; Timothy A Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-28       Impact factor: 11.205

6.  Gene set enrichment analysis made simple.

Authors:  Rafael A Irizarry; Chi Wang; Yun Zhou; Terence P Speed
Journal:  Stat Methods Med Res       Date:  2009-12       Impact factor: 3.021

7.  Analysis of the coding genome of diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Vladimir Trifonov; Giulia Fabbri; Jing Ma; Davide Rossi; Annalisa Chiarenza; Victoria A Wells; Adina Grunn; Monica Messina; Oliver Elliot; Joseph Chan; Govind Bhagat; Amy Chadburn; Gianluca Gaidano; Charles G Mullighan; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

8.  The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.

Authors:  Dan A Landau; Clare Sun; Daniel Rosebrock; Sarah E M Herman; Joshua Fein; Mariela Sivina; Chingiz Underbayev; Delong Liu; Julia Hoellenriegel; Sarangan Ravichandran; Mohammed Z H Farooqui; Wandi Zhang; Carrie Cibulskis; Asaf Zviran; Donna S Neuberg; Dimitri Livitz; Ivana Bozic; Ignaty Leshchiner; Gad Getz; Jan A Burger; Adrian Wiestner; Catherine J Wu
Journal:  Nat Commun       Date:  2017-12-19       Impact factor: 14.919

9.  Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.

Authors:  Neus Giménez; Alejandra Martínez-Trillos; Arnau Montraveta; Mónica Lopez-Guerra; Laia Rosich; Ferran Nadeu; Juan G Valero; Marta Aymerich; Laura Magnano; Maria Rozman; Estella Matutes; Julio Delgado; Tycho Baumann; Eva Gine; Marcos González; Miguel Alcoceba; M José Terol; Blanca Navarro; Enrique Colado; Angel R Payer; Xose S Puente; Carlos López-Otín; Armando Lopez-Guillermo; Elias Campo; Dolors Colomer; Neus Villamor
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

View more
  14 in total

Review 1.  Understanding CLL biology through mouse models of human genetics.

Authors:  Elisa Ten Hacken; Catherine J Wu
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476

2.  TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.

Authors:  Amy L Whillock; Tiffany K Ybarra; Gail A Bishop
Journal:  J Biol Chem       Date:  2021-02-25       Impact factor: 5.486

Review 3.  Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective.

Authors:  Marwan Kwok; Catherine J Wu
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

4.  Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.

Authors:  Wenjing Zhang; Fuyan Shi; Yujia Kong; Yuting Li; Chao Sheng; Suzhen Wang; Qinghua Wang
Journal:  Cancer Med       Date:  2021-12-04       Impact factor: 4.452

Review 5.  Biology and Treatment of Richter Transformation.

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

Review 6.  DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.

Authors:  Ruixue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-09

Review 7.  Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.

Authors:  C I Edvard Smith; Jan A Burger
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 8.  Exploring the pathways to chronic lymphocytic leukemia.

Authors:  Freda K Stevenson; Francesco Forconi; Thomas J Kipps
Journal:  Blood       Date:  2021-09-09       Impact factor: 25.476

Review 9.  Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives.

Authors:  Marwan Kwok; Angelo Agathanggelou; Nicholas Davies; Tatjana Stankovic
Journal:  Cancers (Basel)       Date:  2021-09-18       Impact factor: 6.639

10.  CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.

Authors:  Ulrich Keller; Stefan Habringer; Richard Lewis; H Carlo Maurer; Nikita Singh; Irene Gonzalez-Menendez; Matthias Wirth; Markus Schick; Le Zhang; Konstandina Isaakidis; Anna Katharina Scherger; Veronika Schulze; Junyan Lu; Thorsten Zenz; Katja Steiger; Roland Rad; Leticia Quintanilla-Martinez; Marion Espeli; Karl Balabanian
Journal:  Leukemia       Date:  2021-08-06       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.